Pieno Žvaigždės AB, Financial statements for the year 2024

Click here - to use the wp menu builder

News Room

Less than 1 min.Read

By Investing Today

April 25, 2025

Financial statements, Management report, Confirmation of the management, Audit opinion and Sustainability report for 2024 approved by the Annual General Shareholders’ Meeting of Pieno Žvaigždės AB on 25 April 2025.

Laimonas Vaškevičius

CFO

+370 5 246 1419

Attachments

2024_ar_en_eur_solo_ias_esef
Pieno žvaigždės AB – CSRD limited assurance report EN
Pieno_Zvaigzdes_AB-Opinion_24_IFRS_SA_ESEF_EN_esigned_20250328

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

SANOMA CORPORATION: ACQUISITION OF OWN SHARES 25 April 2025

Credit Agricole Nord de France – Resultats Financiers au 31 Mars 2025

Pieno Žvaigždės AB, Financial statements for the year 2024

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual...

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Tesla Prepares for Robotaxi Reveal in June, Insiders Share Secrets

Rubio Shutters Climate Office, Alarming Global Climate Advocates

Topics

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual...

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Tesla Prepares for Robotaxi Reveal in June, Insiders Share Secrets

Rubio Shutters Climate Office, Alarming Global Climate Advocates

Trump’s Second Term Viewed as ‘Chaotic’ and ‘Scary’ by Majority of Voters

Why Shaq Won’t Share His $500 Million Fortune With His Kids: ‘We Ain’t Rich. I’m Rich. I’m Not Going to Hand It to You,...

Trump’s Approval Plummets As Tariffs Bite, Americans Expect Skyrocketing Prices and Shrinking Wallets

Related Articles

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual...

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Tesla Prepares for Robotaxi Reveal in June, Insiders Share Secrets

Rubio Shutters Climate Office, Alarming Global Climate Advocates

Company

Headlines

Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual...

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025

Tesla Prepares for Robotaxi Reveal in June, Insiders Share Secrets

Newsletter